Psychedelic Decriminalization Support Flat For Two Years, UC Berkeley Survey Finds

Voter support for psychedelic research, therapy and prescription access all surged. Decrim didn’t move. A new Berkeley survey says it out loud.

Decriminalization is the line that didn’t move.

Two years of polling. Every other major psychedelic policy idea tracked by the UC Berkeley Center for the Science of Psychedelics gained ground with American voters. Support for making psychedelic research easier jumped 14 points. Backing for prescription-medicine access climbed 12. Therapeutic-use legalization rose 10. The numbers point at the doctor’s office.

Removing criminal penalties for personal possession? Twenty-nine percent in 2023. Twenty-eight percent in 2025. Nonsignificant.

Read that again. The decrim wing has been pushing the same argument for two years, and the public has not moved an inch.

That’s the takeaway in A Rising Tide of Cautious Support, the second annual UC Berkeley Psychedelics Survey, released this month. The headline numbers tell a story of momentum. The breakdown tells a different one. The psychedelic movement is winning on medical terms and losing on liberation terms. The gap is widening fast.

The Numbers That Moved, And The One That Didn’t

BCSP surveyed 1,577 registered voters between April 16 and 28, 2025. FM3 Research handled sampling and weighting. Margin of error: plus or minus 2.5 points.

Worth flagging upfront: the survey was funded by two anonymous donors. Doesn’t disqualify anything, but it’s the detail skeptics will hammer if it isn’t named.

The advocacy ecosystem has spent the past two years pushing on every front. Local decriminalization measures have multiplied. State legislatures have considered psychedelic bills in roughly half the country. A federal executive order earlier this year focused on expanding research into psychedelic-based mental health treatments. The activity is real. The polling number didn’t notice.

Medicine Sells. Liberation Doesn’t.

The clearest illustration of the split shows up when voters are asked who, specifically, should have access.

Given a choice between full prohibition, regulated therapeutic access or decriminalization for different populations, voters extended majority support to people receiving end-of-life care, military veterans, people with depression and people with addiction. 86% of voters back either regulated therapeutic access or removal of criminal penalties for people in end-of-life care. The strongest single number in the report.

Adults over 21? Thirty-seven percent support regulated therapeutic access. Twenty-six percent back decriminalization for that group. Twenty-six percent still say it should be illegal.

Watch this. Veterans, the depressed, the addicted and the dying all get majority approval for regulated access. Adults who just want to use psychedelics get a quarter of the country wanting them in jail.

The message tracks across the data. Voters want psychedelics available to people they see as sick, hurting or running out of options. They are not signing off on the right to use psychedelics because you want to.

What The Movement Doesn’t Want To Hear

The cognitive liberty wing of the psychedelic movement has been the philosophical engine of the policy fight since the 1970s. Personal use. Bodily sovereignty. The right not to be told what you can put in your own consciousness. Decrim ballot measures in Denver, Oakland and beyond were powered by that argument before therapeutic frameworks took the stage.

Parts of that advocacy wing have, at times, viewed the medicalization track with suspicion. Pharmaceutical capture. Regulatory gatekeeping. A “psychedelic exceptionalism” that wins access for clinical uses while the broader drug war grinds on.

Two years of survey data suggest the public has chosen sides in that quiet civil war. Not the side the cognitive liberty wing built its identity on.

The Stigma Underneath

The medical lane is winning, but only by so much. Beneath the policy numbers sits a layer of social stigma the press release didn’t lead with.

Asked which words describe people who use psychedelics “pretty” or “extremely” well, voters most often picked “open-minded” (48%) and “creative” (37%). Then the floor drops out. “Moral” and “smart” describe psychedelic users well to just 16-17% of voters. About a quarter still land on “addicts” (24%) and “irresponsible” (24%).

The picture sharpens by demographic. Conservative voters describe psychedelics as a “cause of crime” at twice the liberal rate (37% versus 17%). They also rate users as “addicts” or “irresponsible” at significantly higher levels. Black voters reported the largest jump in exposure to psychedelics of any demographic group, up 15 points since 2023, the biggest shift in the dataset. They also report significantly higher safety concerns: 50% say “addictive” describes psychedelics well, compared to 34% of non-Black voters.

Exposure is rising. Stigma isn’t dissolving in step.

The Constituency, And Who It Doesn’t Include

The psychedelic renaissance has a constituency. Veterans. People at the end of their lives. Patients who have run out of conventional options. The clinical class. The research class. Voters who want a regulated path for someone they see as deserving.

It doesn’t, yet, include the person who just wants the right to use psychedelics on a Saturday night. That constituency built the movement. The data say it is the one the public isn’t moving with.

But here’s where this lands.

The wave is real. It just isn’t breaking where the movement built its beach.